文献速递炎症性肠病

综述:炎症性肠病中抗肿瘤坏死因子治疗不良事件的管理

Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2019-02-08

本文通过检索Medline和Pubmed并参考相关国际指南,综述了抗肿瘤坏死因子(anti-TNF)治疗炎症性肠病(IBD)可能引发的输注反应、血液系统疾病、感染(细菌、病毒、真菌及机会性感染)、自身免疫、皮肤、心脏和神经系统疾病以及恶性肿瘤等不良事件,并讨论了这些事件的管理。

要点

  • 抗肿瘤坏死因子治疗在少数患者中可导致显著并发症和死亡。
  • 不良事件包括输注反应、血液病、感染、自身免疫病、皮肤病、心脏病、神经病及恶性肿瘤。
  • 消化内科医生需理解这些效应的机制,快速识别并恰当管理。

核心结论

  • 抗肿瘤坏死因子治疗对免疫系统有广泛影响,在少数患者中导致一系列潜在不良事件。

研究设计与样本

  • 综述:通过Medline和Pubmed检索,检索词包括「抗肿瘤坏死因子」「英夫利西单抗」或「阿达木单抗」或「戈利木单抗」结合「溃疡性结肠炎」或「克罗恩病」或「炎症性肠病」,并筛选包含「并发症」「副作用」或「不良事件」或「安全性」的文章,同时参考相关国际指南。

主要发现

  • 讨论的不良事件包括输注反应、血液系统疾病和感染(包括细菌、病毒、真菌及机会性感染)以及自身免疫、皮肤、心脏和神经系统疾病,还包括实体器官、血液系统及病毒相关恶性肿瘤。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biological therapy is currently widely used to treat IBD. Infliximab, adalimumab and golimumab are currently licensed anti-TNF therapies. Biosimilar anti-TNF monoclonal antibodies are increasingly used. Anti-TNF therapies are widely used and their adverse effects are well characterised, and may cause significant morbidity and mortality in a small proportion of exposed patients. Gastroenterologists need to understand the mechanisms for these effects, recognise these swiftly and manage such events appropriately. AIM: To cover the range of potential adverse reactions as a result of biologic therapy and specifically management of these events. METHODS: A Medline and Pubmed search was undertaken. Search terms included were "anti-TNF," "infliximab" or "adalimumab" or "golimumab" combined with the keywords "ulcerative colitis" or "Crohn's disease" or "inflammatory bowel disease" and then narrowed to articles containing the keywords "complications," "side effects" or "adverse events" or "safety profile." International guidelines were also reviewed where relevant. RESULTS: Adverse events discussed in this review include infusion reactions, blood disorders and infections (including bacterial, viral, fungal and opportunistic infections) as well as autoimmune, dermatological disorders, cardiac and neurological conditions. Malignancies including solid organ, haematological and those linked to viral disease are discussed. CONCLUSIONS: Anti-TNF therapy has wide-ranging effects on the immune system resulting in a spectrum of potential adverse events in a small proportion of patients. Research advances are improving the understanding, recognition and management of these adverse events.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Shivaji UN, Sharratt CL, Thomas T, et al. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2019. PMID: 30735257. doi:10.1111/apt.15097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。